Association of the genetic polymorphisms of NFKB1 with susceptibility to ovarian cancer

Genetics and Molecular Research

Volumn 14, Issue 3, 2015, Pages 8273-8282

  Chen, L P ^a   Cai, P S ^a   Liang, H B ^a  

^a Integrated Traditional Chinese and Western Medicine Hospital of Wenzhou   (China)

Author keywords

Nuclear factor B; Ovarian cancer; Single nucleotide polymorphisms

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NFKB1 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; HAN CHINESE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MIDDLE AGED; NFKB1 GENE; OVARY CANCER; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; INDEL MUTATION; OVARY TUMOR; RISK FACTOR;

ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INDEL MUTATION; INTRONS; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 84938053758     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.July.27.15     Document Type: Article

References (35)

1. Annunziata CM, Stavnes HT, Kleinberg L, Berner A, et al. (2010). Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer 116: 3276-3284.
2. Barrett JC, Fry B, Maller J and Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
3. Bernal-Mizrachi L, Lovly CM and Ratner L (2006). The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc. Natl. Acad. Sci. U. S. A. 103: 9220-9225.
4. Cai H, Sun L, Cui L, Cao Q, et al. (2013). A functional insertion/deletion polymorphism (-94 ins/del ATTG) in the promoter region of the NFKB1 gene is related to the risk of renal cell carcinoma. Urol. Int. 91: 206-212.
5. Chen F, Castranova V, Shi X and Demers LM (1999). New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin. Chem. 45: 7-17.
6. Chen F, Castranova V and Shi X (2001). New insights into the role of nuclear factor-kappaB in cell growth regulation. Am. J. Pathol. 159: 387-397.
7. Curtis D, Knight J and Sham PC (2006). Program report: GENECOUNTING support programs. Ann. Hum. Genet. 70: 277-279.
8. Fan Y, Yu W, Ye P, Wang H, et al. (2011). NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population. DNA Cell Biol. 30: 241-245.
9. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, et al. (2002). The structure of haplotype blocks in the human genome. Science 296: 2225-2229.
10. Glauert HP, Tharappel JC, Banerjee S, Chan NL, et al. (2008). Inhibition of the promotion of hepatocarcinogenesis by 2,2',4,4',5,5'-hexachlorobiphenyl (PCB-153) by the deletion of the p50 subunit of NF-kappa B in mice. Toxicol. Appl. Pharmacol. 232: 302-308.
11. Gulden C and Olopade OI (2010). Risk assessment and genetic testing for ovarian cancer. AJR Am. J. Roentgenol. 194: 309-310.
12. Hernandez L, Hsu SC, Davidson B, Birrer MJ, et al. (2010). Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 70: 4005-4014.
13. Huo ZH, Zhong HJ, Zhu YS, Xing B, et al. (2013). Roles of functional NFKB1 and β-TrCP insertion/deletion polymorphisms in mRNA expression and epithelial ovarian cancer susceptibility. Genet. Mol. Res. 12: 3435-3443.
14. Jemal A, Siegel R, Xu J and Ward E (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60: 277-300.
15. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, et al. (2004). Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum. Mol. Genet. 13: 35-45.
16. Karin M (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
17. Karin M (2009). NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 1: a000141.
18. Karsan A, Yee E, Kaushansky K and Harlan JM (1996). Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Blood 87: 3089-3096.
19. Kumar S and Baglioni C (1991). Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J. Biol. Chem. 266: 20960-20964.
20. LaCasse EC, Baird S, Korneluk RG and MacKenzie AE (1998). The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259.
21. Lewander A, Butchi AK, Gao J, He LJ, et al. (2007). Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand. J. Gastroenterol. 42: 1332-1338.
22. Li P, Gu J, Yang X, Cai H, et al. (2013). Functional promoter-94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PloS One 8: e71604.
23. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, et al. (2007). Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin. Cancer Res. 13: 3423-3430.
24. Maeda S and Omata M (2008). Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 99: 836-842.
25. Naugler WE and Karin M (2008). NF-kappaB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18: 19-26.
26. Riemann K, Becker L, Struwe H, Rübben H, et al. (2007). Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int. J. Clin. Pharmacol. Ther. 45: 423-430.
27. Shukla S, Maclennan GT, Marengo SR, Resnick MI, et al. (2005). Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 64: 224-239.
28. Sun XF and Zhang H (2007). NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol. Histopathol. 22: 1387-1398.
29. Yang L, Cohn L, Zhang DH, Homer R, et al. (1998). Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation. J. Exp. Med. 188: 1739-1750.
30. Yang X, Li PI, Tao JI, Qin C, et al. (2014). Association between NFKB1-94ins/del ATTG Promoter Polymorphism and Cancer Susceptibility: An Updated Meta-Analysis. Int. J. Genomics 2014: 612972.
31. Yu Y, Wan Y and Huang C (2009). The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target. Curr. Cancer Drug Targets 9: 566-571.
32. Zhao JH, Curtis D and Sham PC (2000). Model-free analysis and permutation tests for allelic associations. Hum. Hered. 50: 133-139.
33. Zhao JH, Lissarrague S, Essioux L and Sham PC (2002). GENECOUNTING: haplotype analysis with missing genotypes. Bioinformatics 18: 1694-1695.
34. Zhou B, Qie M, Wang Y, Yan L, et al. (2010). Relationship between NFKB1-94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk. Ann. Oncol. 21: 506-511.
35. Zou YF, Yuan FL, Feng XL, Tao JH, et al. (2011). Association between NFKB1-94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis. Cancer Invest. 29: 78-85.